eFFECTOR Therapeutics

eFFECTOR Therapeutics Gross Margin

Gross Margin of eFFECTOR Therapeutics (EFTR) as of Oct 17, 2026.

Gross Margin

-

Last updated:

Gross Margin of eFFECTOR Therapeutics is 2026 - . Gross Margin of eFFECTOR Therapeutics was 2025 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

eFFECTOR Therapeutics Stock analysis

What does eFFECTOR Therapeutics do? eFFECTOR Therapeutics Inc, based in Solana Beach, US, is a clinical-stage biopharmaceutical company specializing in oncology drug development. The company focuses on selective translation regulator inhibitors (STRIs), targeting the eIF4F complex and MNK kinase. Its lead candidate tomivosertib, in a Phase 2b trial with KEYTRUDA for metastatic NSCLC, and second candidate zotatifin, in Phase 1/2 trials for solid tumors, are part of its pipeline. The company, listed on January 8, 2021, employs 15 people. eFFECTOR Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about eFFECTOR Therapeutics stock

On Eulerpool you can find the complete historical development of Gross Margin eFFECTOR Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's eFFECTOR Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — eFFECTOR Therapeutics

All Key Metrics — eFFECTOR Therapeutics